The 2022 Tandem Meetings | VRD induction, Mel200-conditioned autoHSCT and lenalidomide maintenance in multiple myeloma
Mahmoud Gaballa, MD, Institution: Massachusetts General Hospital, Boston, MA, discusses the results of a study assessing the long-term outcomes of patients with multiple myeloma treated with bortezomib, lenalidomide and dexamethasone (VRD) induction, melphalan-conditioned autologous hematopoietic stem cell transplantation (autoHSCT) and lenalidomide maintenance. Overall, the study showed that this treatment regimen is associated with good outcomes in multiple myeloma, especially in patients with standard-risk cytogenetics. This interview took place at the Transplantation & Cellular Therapy (TCT) Meetings of ASTCT™ and CIBMTR® 2022 in Salt Lake City, Utah.
Transcript (edited for clarity)
We looked at the outcomes of 187 multiple myeloma patients who were treated in a single center and they were treated with VRD induction followed by autologous stem cell transplantation with melphalan 200 conditioning and lenalidomide maintenance. After induction, the CR rate was 9.6% and VGPR or better, was 52.9%. And at day 100 post-transplantation, those responses improved to 29.4% CR or stringent CR and 74...
We looked at the outcomes of 187 multiple myeloma patients who were treated in a single center and they were treated with VRD induction followed by autologous stem cell transplantation with melphalan 200 conditioning and lenalidomide maintenance. After induction, the CR rate was 9.6% and VGPR or better, was 52.9%. And at day 100 post-transplantation, those responses improved to 29.4% CR or stringent CR and 74.9% VGPR or better. The 5-year PFS was 43.1% and OS was 79% overall. High-risk cytogenetics were associated with worse outcomes. So, overall, our study showed that this standard of care regimen has good outcomes, especially in patients with standard-risk cytogenetics. However, recent developments such as using front-line quadruplet regimens or other drugs, all that is available on progression, has led to improved outcomes.
Read more...
